Massive rise in prevalence of menopausal vasomotor symptoms and active participation of government and private healthcare bodies in improving awareness about women’s health in the past few significantly stimulated the growth of the global market for menopausal hot flashes. The market is on the cusp of a major transformation, owing majorly to the declining popularity of hormone-based therapies and patent expiries of blockbuster drugs and products.
Transparency Market Research marks that the rising demand for non-hormonal drugs and products for treating menopausal hot flashes will have a sizeable impact on the overall development of the market in the next few years. The major dearth of such alternatives in the global menopausal hot flashes market’s present product portfolio will result in the moderate growth prospects of the market through 2023. This factor, along with patent expiries of key products and drugs point the threat of generic drugs taking over the market in the next few years.
TMR analysts suggest that the market will expand at a CAGR of nearly 3.7% from 2015 to 2023. The market, which had an opportunity of US$ 3,774.5 mn in 2014, will rise to a valuation of US$5,284.1 mn by 2023.
Non-hormonal Therapies to Gain Traction
Hormone replacement therapies, comprising hormones such as estrogen and progestin remained at the forefront of treatment of menopausal hot flashes for a long time. However, several studies in the recent past have linked hormone therapies with a rise in health concerns such as a number of cancers and cardiovascular diseases in women. This has led to a sizeable decline in the overall global demand for hormone-based therapies for menopausal hot flashes. Through the segment dominated in the past, accounting for over 95% in the overall market in 2014, it is expected to expand at a mere 3.2% CAGR through 2023.
In stark contrast, the demand for non-hormonal therapies for menopausal hot flashes will rise at a handsome 13.8% CAGR over the period between 2015 and 2023. The segment of non-hormonal therapies will not be able to surpass the segment of hormonal therapies anytime soon owing to the latter’s excellent penetration in the global market. But the focus of product manufacturers on this segment will see a massive rise.
North America to Lead but Developing Regions to Provide Most Promising Growth Opportunities
North America is presently the leading regional market for menopausal hot flashes owing to the high prevalence of menopausal vasomotor symptoms in the region. It accounted for a massive 66% share in the global menopausal hot flashes market in 2014. Europe followed with a comparatively moderate 17.9% share in the global market in the same year. The high awareness about the condition among women along with the rising population of women aged between 40-65 years will enable these regions to be the most prominent drivers of the global market through 2023 as well.
However, the market will also witness increased traction in Asia Pacific, where it will exhibit the highest CAGR of 6.7% over the period between 2015 and 2023. The swooping rise in health awareness among women, rising disposable incomes, and a large population base of women more in the age brackets of 35 and 65 years will be the key factors driving the market in Asia Pacific.
The highly fragmented global market for menopausal hot flashes had the top eight companies account for nearly 50% share in 2014. Some of the leading vendors in the market are Pfizer, Inc., Novartis AG, Novo Nordisk, Teva Pharmaceutical Industries Ltd., Hisamitsu Pharmaceutical Co., Inc.
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
2. Executive Summary
2.1. Menopausal Hot Flashes Market Snapshot
2.2. Global Menopausal Hot Flashes Market Share, by Geography, 2014 & 2023 (Value %)
2.3. Global Menopausal Hot Flashes Market Revenue, by Geography, 2014 (US$ Mn)
2.4. Global Menopausal Hot Flashes Market, by Therapy, 2014 (US$ Mn)
3. Menopausal Hot Flashes Market - Industry Analysis
3.2. Market Dynamics
18.104.22.168. Rise in menopausal vasomotor symptoms across the globe
22.214.171.124. Approval of new treatment options
126.96.36.199. Growing women health awareness
188.8.131.52. Risk of breast cancer with HRT treatment
184.108.40.206. Growing demand for alternative therapies
220.127.116.11. Emerging economies to offer sustained growth opportunities
3.3. Market Attractiveness Analysis, by Geography, 2014
3.4. Competitive Landscape, Market Share Analysis, by Key Players, 2014 (Value %)
4. Market Segmentation – By Therapy
4.2. Global Menopausal Hot Flashes Revenue, by Therapy, 2013–2023 (US$ Mn)
4.3. Global Menopausal Hot Flashes Market Revenue, by Product, 2013–2023, (US$ Mn)
4.4. Global Hormonal Therapy Market Revenue, by Product, 2013–2023, (US$ Mn)
4.4.1. Global Estrogen Market Revenue, 2013–2023, (US$ Mn)
18.104.22.168. Global Premarin Flashes Market Revenue, 2013–2023, (US$ Mn)
22.214.171.124. Global Vivelle-Dot Market Revenue, 2013–2023, (US$ Mn)
4.4.2. Global Progestin Market Revenue, 2013–2023, (US$ Mn)
126.96.36.199. Global Prometrium Market Revenue, 2013–2023, (US$ Mn)
4.4.3. Global Combination Therapy Market Revenue, 2013–2023, (US$ Mn)
188.8.131.52. Global Duavee Market Revenue, 2013–2023, (US$ Mn)
184.108.40.206. Global Prempro Market Revenue, 2013–2023, (US$ Mn)
4.5. Global Non-hormonal Market Revenue, 2013–2023, (US$ Mn)
4.5.1. Global Brisdelle Market Revenue, 2013–2023, (US$ Mn)
5. Pipeline Analysis
5.1. Phase I and II Drugs, Tabular Representation
5.2. Menopausal Hot Flashes Phase III Drugs Market Revenue, 2017 - 2023 (USD Million)
6. Market Segmentation – By Geography
6.1. Global Menopausal Hot Flashes Market Revenue, by Geography, 2013–2023
6.1.1. North America Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.2. Europe Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.3. Asia Pacific Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.4. Rest of the World Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
8. Company Profiles
8.1. Allergan plc
8.2. Bayer AG
8.3. Hisamitsu Pharmaceutical Co., Inc.
8.4. Merck & Co., Inc.
8.5. Novartis International AG
8.6. Novo Nordisk
8.7. Pfizer, Inc.
8.8. Teva Pharmaceutical Industries Ltd.
This report on the menopausal hot flashes market studies the current and future prospects of the treatment across the globe. Hot flashes are common symptoms experience by women in menopause transition. Hot flashes are defined as ephemeral, recurring periods of heat sensation and redness, often associated with sweat and are experienced by about 75% of women in the U.S and Europe at some point before or during the menopause period. These tend to decrease in severity and frequency over a few months to a few years, but sometimes persist into old age.
The menopausal hot flashes market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global menopausal hot flashes drugs market with respect to the segments based on the type of therapy, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global menopausal hot flashes market.
Based on therapy type, the menopausal hot flashes market has been segmented into two major categories: hormonal and non-hormonal treatment. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.
Geographically, the global menopausal drugs market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, Rest of Europe), Asia Pacific (Japan, Australia, India, China, Rest of Asia Pacific), and Rest of the World (Latin America, Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global menopausal hot flashes market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co. Inc., Novartis International AG, Novo Nordisk, Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.
The global menopausal hot flashes market is segmented as follows:
Global Menopausal Hot Flashes Market, by Therapy Type
- Combination Therapy
Global Menopausal Hot Flashes Market, Pipeline Analysis
- Phase I and II Drugs
- Phase III Drugs
Global Menopausal Hot Flashes Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Rest of the World
- Latin America
- Middle East and Africa